Aniracetam

Overview of Aniracetam

Aniracetam is a nootropic agent belonging to the racetam family. It has been studied for its effects on neuronal activity and receptor binding in the brain.

Aniracetam
PubChem CID	2196
Molecular Formula	C12H13NO3
Molecular Weight	219.24 g/mol
Synonyms	1-(4-Methoxybenzoyl)-2-pyrrolidinone; Draganon; Sarpul
IUPAC	1-(4-methoxybenzoyl)pyrrolidin-2-one
CAS	72432-10-1
Labeling	For research use only. Not for human or animal consumption.
Chemical Structure Depiction
Purity	≥98%
Classification	Cholinergic nootropic; Pyrrolidinone derivative
Storage Temperature	Store at -20°C or as recommended by the supplier.

What is Aniracetam?

Aniracetam is a type of nootropic compound that may affect brain activity. It was first made in the 1970s by the Swiss company Hoffman-La Roche. It belongs to the racetam family, which has a similar chemical structure. Other racetams include Oxiracetam and Phenylpiracetam.

Aniracetam is fat-soluble, meaning it can cross the blood-brain barrier. Studies show it has a short half-life of 30‑40 minutes.

How Does Aniracetam Work?

Aniracetam activates AMPA-type glutamate receptors in brain cells. This is thought to increase the number of AMPA receptor sites, allowing more calcium to enter the cells and raising the level of calcium inside.

Research also suggests that Aniracetam may affect the following processes:

• Increases acetylcholine transmission in the brain.

• Reduces dopamine levels in specific regions of the brain.
• Modulates serotonin levels in some brain regions.

Aniracetam Research

Aniracetam has been extensively studied in laboratory settings. Studies have looked at how Aniracetam affects brain cell activity and receptors. This helps understand its possible impact on neurotransmitters.

Why Choose PureRawz for Aniracetam?

Buy Aniracetam for laboratory research use from our online shop. At Purerawz, we provide high-quality reference materials. Each research compound comes with a Certificate of Analysis for verification of purity and concentration.

Note:

Aniracetam is an investigational compound currently undergoing clinical evaluation and has not been established as safe or effective for any therapeutic use

Disclaimer

This information is for educational purposes only and not medical advice. Products are for research use only. Research must follow IRB or IACUC guidelines. Verify information independently before purchasing. By ordering, you agree to our Terms and Conditions. If you are not 100% satisfied with the product you received, please contact us at support@staging.purerawz.co

ATTENTION: All our products are for LABORATORY AND RESEARCH PURPOSES ONLY, not for veterinary or human use.

Reference Links:

PubChem. (n.d.-a). Aniracetam (CID 2196). PubChem Compound Database. U.S. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/2196

Lee, C. R., & Benfield, P. (1994b). Aniracetam. Drugs & Aging, 4(3), 257–273. https://doi.org/10.2165/00002512-199404030-00007

Petkov, V. D., Grahovska, T., Petkov, V. V., Konstantinova, E., & Stancheva, S. (1984). Changes in the brain biogenic monoamines of rats, induced by piracetam and aniracetam. (1984b). PubMed.  https://pubmed.ncbi.nlm.nih.gov/6535371/

Koliaki, C. C., Messini, C., & Tsolaki, M. (2011b). Clinical Efficacy of Aniracetam, Either as Monotherapy or Combined with Cholinesterase Inhibitors, in Patients with Cognitive Impairment: A Comparative Open Study*. CNS Neuroscience & Therapeutics, 18(4), 302‑312. https://doi.org/10.1111/j.1755-5949.2010.00244.x

Nakamura, K. (2002b). Aniracetam: Its novel therapeutic potential in Cerebral Dysfunctional Disorders based on recent pharmacological discoveries. CNS Drug Reviews, 8(1), 70‑89.

https://doi.org/10.1111/j.1527-3458.2002.tb00216.x